Picture of IDEXX Laboratories logo

IDXX — IDEXX Laboratories News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

IDEXX Laboratories Q3 revenue beats estimates, lifts FY profit outlook

IDEXX Laboratories Q3 revenue beats estimates, lifts FY profit outlook 


Overview

  • U.S. pet diagnostics firm's Q3 revenue rose 10%, beating analyst expectations

  • Q3 EPS increased 18% to $4.01

  • Company raised 2026 revenue and EPS guidance on strong recurring revenue growth


Outlook

  • IDEXX raises 2026 revenue outlook to $4.74 bln-$4.77 bln, up $32 mln at midpoint

  • Company increases 2026 EPS guidance to $14.96-$15.16, up $0.25 from prior midpoint

  • IDEXX lowers 2026 operating margin outlook to 32.1%-32.3% from previous 32.3%-32.5%


Result Drivers

  • CAG DIAGNOSTICS RECURRING REVENUE - Double-digit growth driven by strong same-store volume, customer gains, and expanded instrument base

  • INNOVATION AND PRODUCT LAUNCHES - New analyzers and expanded diagnostic panels contributed to revenue growth

  • PRICE REALIZATION AND PRODUCTIVITY - Net price gains and operational productivity supported margin expansion


Company press release: ID:nBw11RmwGa


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$1.21 bln

$1.19 bln (10 Analysts)

Q3 EPS

$4.01

Q3 Gross Margin

62.90%

Q3 EBIT Margin

33.10%


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for IDEXX Laboratories, Inc. is $707.50, about 28.4% above its October 30 closing price of $551.21

  • The stock recently traded at 34 times the next 12-month earnings vs. a P/E of 36 three months ago


Reuters Recommended Reads

  • Oct 30 - AstraZeneca CEO strikes bullish tone on pipeline as stock rallies

  • Oct 30 - India orders Sun Pharma to halt eye-care drug production at plant after quality lapses


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on IDEXX Laboratories

See all news